THC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tenet Healthcare Corp (THC) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock is currently oversold based on RSI, has strong financial performance, positive analyst sentiment, and hedge fund buying activity. Despite the lack of immediate AI or SwingMax trading signals, the long-term growth potential and positive demographic trends make this a solid investment opportunity.
The stock is currently oversold with an RSI of 19.284, indicating a potential rebound. The MACD histogram is negative (-4.288) but contracting, suggesting bearish momentum is weakening. The stock is trading near its key support level (S1: 196.787), which could act as a floor for the price. Moving averages are converging, signaling potential price stabilization.
Strong Q4 financial performance with revenue up 8.95% YoY, net income up 16.67% YoY, and EPS up 27.88% YoY.
Hedge funds are significantly increasing their positions, with a 337.36% increase in buying activity.
Analysts have consistently raised price targets, with the highest target at $283, indicating substantial upside potential.
Positive demographic trends and focus on higher acuity surgeries provide long-term growth tailwinds.
Gross margin slightly declined (-0.40% YoY), which could indicate rising costs or pricing pressures.
The MACD remains negative, signaling that bearish momentum has not fully reversed.
No recent news or congress trading data to act as immediate catalysts.
In Q4 2025, Tenet Healthcare delivered strong financial results: Revenue increased by 8.95% YoY to $5.53 billion, net income rose by 16.67% YoY to $371 million, and EPS grew by 27.88% YoY to 4.22. However, gross margin slightly declined to 77.55%, down 0.40% YoY.
Analysts are overwhelmingly positive on THC, with multiple firms raising price targets recently. Guggenheim has the highest target at $283, citing an 'easy set-up' for Q1 and manageable growth expectations. RBC Capital highlights the stock as their favorite hospital name, citing strong fundamentals and undervaluation. Overall, analysts maintain Buy or Outperform ratings, reflecting confidence in the company's growth trajectory.
